Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Let’s review some key updates to the revised CDC PrEP guidelines released in 2021.
Before continuing, please take a moment to answer the following questions.
The CDC guidelines on PrEP were updated in 2021 to coincide with the FDA approval of cabotegravir (CAB) as the first extended-release injectable PrEP product.4 Among key updates is the recommendation that we broaden our message to make sure everyone who might benefit from PrEP is aware of its availability by discussing it with all sexually active patients and prescribing it to anybody who asks for it.
Recommendations on HIV testing also have been revised. HIV status now should be assessed at follow-up visits during and recently after PrEP with an HIV-1 RNA qualitative or quantitative assay for everyone receiving oral and injectable PrEP. The recommended frequency for testing is every 3 months with oral PrEP and every 2 months with long-acting (LA) injectable CAB. In the HPTN 083 study of LA injectable CAB vs daily oral PrEP in men who have sex with men (MSM) and transgender women (TGW), HIV detection with antigen or antibody testing was delayed compared with qualitative HIV-1 RNA testing in both groups.5
Revised recommendations on renal monitoring advise that individuals who are not at risk for renal disease—that is, people younger than 50 years of age with estimated creatinine clearance (CrCl) ≥90 mL/min—need only annual renal monitoring if receiving oral PrEP with either TDF or TAF in combination with FTC. People receiving oral PrEP who do not meet these criteria should receive renal monitoring every 6 months. People receiving CAB PrEP do not need renal monitoring.
Finally, annual monitoring of triglycerides and cholesterol is recommended for those receiving oral FTC/TAF PrEP in recognition of the elevated triglyceride levels and weight gain seen with use of FTC/TAF compared with FTC/TDF among men in the DISCOVER trial.6